Active, not recruitingPhase 3NCT04293185
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genetix Biotherapeutics Inc.
- Principal Investigator
- Anjulika Chawla, MD, FAAPbluebird bio, Inc.
- Intervention
- bb1111(genetic)
- Enrollment
- 35 enrolled
- Eligibility
- 2-50 years · All sexes
- Timeline
- 2020 – 2027
Study locations (9)
- University of Alabama, Birmingham, Alabama, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Duke University, Durham, North Carolina, United States
- Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
- Virginia Commonwealth University (VCU), Richmond, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04293185 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi